Clinical Trials Logo

Filter by:
NCT ID: NCT03027726 Completed - Clinical trials for Overweight Children With Type 2 Diabetes Risk

Prevention of Diabetes in Overweight/Obese Preadolescent Children

PREDIKID
Start date: March 7, 2017
Phase: N/A
Study type: Interventional

Background: The global pandemic obesity has led to increased risk for prediabetes and type 2 diabetes (T2D). Objectives: (i) To evaluate the effect of a 22 weeks multidisciplinary intervention program including exercise on T2D risk in pre-adolescents with high risk to develop T2D, and (ii) To identify the profile of microRNA in circulating exosomes and in blood peripheral mononuclear cells in pre-adolescents with high risk to develop T2D and its response to a multidisciplinary intervention program including exercise.

NCT ID: NCT03027609 Completed - Clinical trials for Pseudomonas Aeruginosa Pneumonia

Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia

Start date: March 29, 2017
Phase: Phase 2
Study type: Interventional

Prospective, double-blind, randomized assessment of the efficacy, safety and pharmacokinetic of Aerucin® as adjunct treatment (in addition to standard of care antibiotics) for pneumonia caused by P. aeruginosa.

NCT ID: NCT03026465 Completed - Clinical trials for Coronary Artery Disease

Vessel Injury in Relation With Strut Thickness Assessed by OCT

VISTA
Start date: February 16, 2017
Phase: Phase 4
Study type: Interventional

The objective of the present study is to determine the relation between vascular injury induced by the stent and strut thickness.

NCT ID: NCT03025880 Completed - Clinical trials for Advanced Breast Cancer

Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC

PANGEA
Start date: June 28, 2017
Phase: Phase 2
Study type: Interventional

Study Design and Treatment: This is a multicenter phase II trial, with an initial exploratory run-in-phase, to evaluate the efficacy and safety of pembrolizumab in combination with gemcitabine in patients with HER2-negative ABC that have previously received anthracyclines and taxanes (unless clinically contraindicated). In hormone receptor positive patients, previous treatment with 2 or more lines of hormone therapy will also be required. Patients must have at least one measurable lesion that can be accurately assessed at baseline and is suitable for repeated assessment by CT, MRI or plan X-ray. Approximately 53 patients (up to a maximum of 65 patients depending on the results of the run-in-phase) will be included in this trial.

NCT ID: NCT03025711 Completed - Breast Neoplasms Clinical Trials

Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine

KNOWHER
Start date: December 1, 2017
Phase:
Study type: Observational

The overall study objective is to evaluate the effectiveness and safety of Trastuzumab emtansine (T-DM1) and Pertuzumab under real-world disease conditions in the Spain, and specifically in patients treated under compassionate use or early access program

NCT ID: NCT03025230 Completed - Clinical trials for Myofascial Pain Syndrome

Dry Needling Versus Intramuscular Stimulation in the Management of the Myofascial Trigger Points

Start date: December 2016
Phase: N/A
Study type: Interventional

Hypothesis The application of intramuscular electrostimulation will be more effectiveness than the dry needling in myofascial trigger points treatment. Objetives: To determine the effectiveness of intramuscular electrostimulation in the treatment of trigger points of the levator scapula muscle for the improvement of pain in mechanical cervicalgia. Participants: Subjects with diagnosed of myofascial pain syndrome in cervical region and active trigger points in levator scapulae muscle, randomly assigned to experimental or control group. Intervention: Control group: one session of dry needling in active trigger points; experimental group: one session of intramuscular stimulation in active trigger points. Main Outcomes Measures: Pain, pressure pain threshold (PPT), active cervical range of motion and strength muscle . The measures will be taken before, after and one week after the interventions.

NCT ID: NCT03024853 Completed - General Population Clinical Trials

Efficacy of Different Versions of the Best Possible Self Intervention

Start date: March 2015
Phase: N/A
Study type: Interventional

The aim of this study is to analyze the efficacy of several variations of an already validated Positive Psychology Intervention (PPI) called Best Possible Self, using Information and Communication Technologies (ICT) in general population. Participants are randomly assigned to one of 4 conditions: BPS PAST condition, BPS PRESENT condition, BPS FUTURE condition, and CONTROL condition (daily activities).

NCT ID: NCT03023878 Completed - Clinical trials for High-risk Diffuse Large B-Cell Lymphoma

Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma

Start date: March 13, 2017
Phase: Phase 2
Study type: Interventional

A phase 2, multicenter, open-label, single arm clinical trial in adults with newly diagnosed aggressive high-risk DLBCL.

NCT ID: NCT03023605 Completed - Pulmonary Embolism Clinical Trials

Analysis of a Training Intervention for Pulmonary Embolism Diagnosis in Emergency Department (APEED)

APEED
Start date: November 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to analyze the clinical impact of an educational intervention on adherence to Clinical Practice Guidelines in an Emergency Department (ED), by using a standardized training, for improving diagnostic sensibility and reducing unnecessary scans, adverse effects and stays in the ED.

NCT ID: NCT03023423 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

DARZALEX
Start date: December 23, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to compare the overall response rate (ORR) in non-small cell lung cancer (NSCLC) participants treated with daratumumab in combination with atezolizumab versus atezolizumab alone.